Trial · NCT07884968
Multimodal Respiratory Physiotherapy in Women Receiving Radiotherapy for Breast Cancer (RESPIRA-BC)
NCT07884968, Not applicable, Completed, University of Alcala
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Multimodal Respiratory Physiotherapy in Women Receiving Radiotherapy for Breast Cancer (RESPIRA-BC). Trials, record NCT07884968. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07884968
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Multimodal Respiratory Physiotherapy in Women Receiving Radiotherapy for Breast Cancer (RESPIRA-BC)
- NCT number
- NCT07884968
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 22 participants, actual
- Lead sponsor
- University of Alcala
- Conditions
- Breast Neoplasms
- Interventions
- Incentive Spirometry (IS) and Positive Expiratory Pressure (PEP) Training, Individualised Exercise Programme (Aerobic and Resistance Training), Patient Education Programme
- First posted
- 2026-10-21
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recruitment Rate | During the recruitment period | Proportion of eligible women who agreed to participate and were enrolled and randomised in the study, expressed as a percentage of all eligible women invited to participate. |
| Primary | Screening-to-Randomisation Yield | During the recruitment period | Description Proportion of women randomised into the study relative to the total number of women assessed for eligibility, expressed as a percentage. |
| Primary | Retention Rate | From randomisation to the final follow-up assessment (six months after radiotherapy). | Proportion of randomised participants who completed all study assessments, expressed as a percentage of the total number of randomised participants. |
| Primary | Attendance at Face-to-Face Physiotherapy Sessions | Throughout the four-week intervention period. | Proportion of individual face-to-face physiotherapy sessions attended relative to the total number of scheduled sessions, expressed as a percentage. |
| Primary | Adherence to the Home-Based Exercise Programme | Throughout the four-week intervention period. | Proportion of intervention weeks during which participants achieved the prescribed exercise target of at least 30 minutes per day, five days per week, expressed as a percentage. |
| Primary | Adherence to Respiratory Training | Throughout the four-week intervention period. | Proportion of intervention weeks during which participants in the experimental group achieved the prescribed respiratory training target of at least 30 minutes per day, five days per week, expressed as a percentage. |
| Primary | Adverse Events Related to the Intervention (Safety) | Throughout the four-week intervention period | Number and proportion of participants experiencing adverse events during the intervention period. Adverse events were recorded and classified according to their type, seriousness, and potential relationship to the study intervention. |
| Secondary | Forced Expiratory Volume in One Second (FEV1) | Before surgery (T0), after surgery (T1), at 3 months after radiotherapy/before intervention (T2), at 4 months after radiotherapy/after intervention (T3), and at 6 months after radiotherapy (T4). Randomisation occurred between T1 and T2 | Forced expiratory volume in one second (FEV1) was assessed using spirometry and expressed as a percentage of the predicted value (% predicted). |
| Secondary | Forced Vital Capacity (FVC) | Before surgery (T0), after surgery (T1), at 3 months after radiotherapy/before intervention (T2), at 4 months after radiotherapy/after intervention (T3), and at 6 months after radiotherapy (T4). Randomisation occurred between T1 and T2 | Forced vital capacity (FVC) was assessed using spirometry and expressed as a percentage of the predicted value (% predicted). |
| Secondary | Diffusing Capacity of the Lung for Carbon Monoxide (DLCOadj) | Before surgery (T0), after surgery (T1), at 3 months after radiotherapy/before intervention (T2), at 4 months after radiotherapy/after intervention (T3), and at 6 months after radiotherapy (T4). Randomisation occurred between T1 and T2 | Lung diffusing capacity for carbon monoxide (DLCO), adjusted for haemoglobin concentration, was assessed using the single-breath diffusion test and expressed as a percentage of the predicted value (% predicted). |
1 to 10 of 17Source ClinicalTrials.gov
See all 17 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07884968
GET https://conductscience.org/api/trials/v1/NCT07884968/registered